KWON YOUNG
CIK: 0001733094
KWON YOUNG's purchase track record
KWON YOUNG has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/24/2023 | ADMA | $98K | +2.3% | +35.9% | +16.2% |
| 10/25/2021 | ADMA | $100K | +13.0% | +60.2% | -5.9% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ADMA | ▲ Buy | Grant | 10,690 | $0 | 2/9/2026 | View on chart |
| ADMA | ▲ Buy | Grant | 10,889 | $0 | 2/19/2025 | View on chart |
| ADMA | ▼ Sell | Open Market | 60,000 | $1.1M | 8/23/2024 | View on chart |
| ADMA | ▲ Buy | Grant | 24,040 | $0 | 2/26/2024 | View on chart |
| ADMA | ▲ Buy | Open Market | 25,000 | $98K | 8/24/2023 | View on chart |
| ADMA | ▲ Buy | Grant | 25,815 | $0 | 3/6/2023 | View on chart |
| ADMA | ▲ Buy | Grant | 26,586 | $0 | 3/7/2022 | View on chart |
| ADMA | ▲ Buy | Open Market | 100,000 | $100K | 10/25/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
ADMA Biologics Draws Investor Attention Amid Market Decline
Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.
ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.